Haining Huang
CEO,
Cytimm Therapeutics
United States
CEO and co-founder of Cytimm Therapeutics.
• More than 20 years of experience in immunology and oncology research and drug discovery
• Currently leading the research and development of Cytimm pipeline focusing on the Immunotherapy of cancer and autoimmune diseases.
• Before this, Dr. Huang initiated and developed the Immunotherapy pipeline as the Vice President of drug discovery in ACEA therapeutics. In Feb 2020, he led the spinning-off of the division from ACEA and co-founded Cytimm Therapeutics.
• Before joining ACEA, Haining was the senior director of immuno-oncology at Oxford Biotherapeutics, where he led the drug discovery process from target identification to preclinical development.
• Prior to that, Haining was a group leader at Sorrento Therapeutics, responsible for the preclinical R&D of CAR-T immunotherapy.
Dr. Huang got his B.A and PhD in Fudan University, and was trained as an immunologist in TSRI, UCSD and LIAI.
Suffix
PhD
)
){kind=logo}
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}